《港股》恆指半日跌148點 友邦挫跌4%成交額逾291億 阿里健康挫6%
美國總統特朗普稱將致函通知各國對等關稅稅率。港匯再觸發弱方兌換保證,金管局兩度買入共逾296億港元,港股早市下跌。恆指低開169點,初段跌幅擴大至379點見23,690點,其後跌幅收窄至136點高見23,932點,半日跌148點或0.6%,報23,921點;國指跌36點或0.4%,報8,611點;恆生科技指數跌24點或0.5%,報5,209點。大市半日成交總額1,576.89億元。
阿里(09988.HK)擬發約120億港元零息可換債,可換取阿里健康(00241.HK)股份,每股初始交換價6.23元。阿里半日股價跌0.6%報105.6元,阿里健康跌6.4%報4.23元。
其他科技股方面,騰訊(00700.HK)、中芯(00981.HK)、京東(09618.HK)、美團(03690.HK)及新東方(09901.HK)跌0.3%至1%,快手(01024.HK)、百度(09888.HK)及網易(09999.HK)升0.5%至0.8%,嗶哩嗶哩(09626.HK)及萬國數據(09698.HK)升5.3%及7.9%,騰訊音樂(01698.HK)升3.9%。手機部件股舜宇(02382.HK)及瑞聲(02018.HK)回吐3%及4.5%。
小米YU7配置引發消費者關注,小米(01810.HK)跌1.2%報57.4元。小鵬(09868.HK)G7售價19.58萬人幣起遠低於預售價,股價挫5.5%報69.9元。其他車股方面,比亞迪(01211.HK)跌0.4%報122.5元,電池股寧德時代(03750.HK)升3.5%報355.6元。
醫藥股榮昌生物(09995.HK)及康方生物(09926.HK)升14.9%及8.2%,恆瑞醫藥(01276.HK)升3.2%。醫藥股樂普生物(02157.HK)折讓近11%配售H股淨籌逾4.6億元,股價跌3.9%。中生製藥(01177.HK)注射用重組人凝血因子VIIA N01獲批上市,股價升1.7%。
金融股方面,匯控(00005.HK)及港交所(00388.HK)跌0.1%及0.6%,友邦(01299.HK)跌4.4%報69.2元,成交額大增至逾291億元 。其他股份方面,新世界發展(00017.HK)跌4.2%,創科(00669.HK)及中國飛鶴(06186.HK)跌2.5%及2.9%,航空股東航(00670.HK)及國航(00753.HK)跌逾3%,南航(01055.HK)跌2.3%。光伏股協鑫科技(03800.HK)及新特能源(01799.HK)升逾3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.